127 related articles for article (PubMed ID: 35760938)
1. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
Mehta P; Paul A; Ahmed S; Cherian S; Panthak A; Benny J; Shenoy P
Clin Rheumatol; 2022 Nov; 41(11):3537-3542. PubMed ID: 35760938
[TBL] [Abstract][Full Text] [Related]
2. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort.
Ahmed S; Mehta P; Paul A; Anu S; Cherian S; Shenoy V; Nalianda KK; Joseph S; Poulose A; Shenoy P
Ann Rheum Dis; 2022 Jun; 81(6):868-874. PubMed ID: 35135831
[TBL] [Abstract][Full Text] [Related]
3. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
Frommert LM; Arumahandi de Silva AN; Zernicke J; Scholz V; Braun T; Jeworowski LM; Schwarz T; Tober-Lau P; Ten Hagen A; Habermann E; Kurth F; Sander LE; Corman VM; Burmester GR; Biesen R; Albach FN; Klotsche J
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597977
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases.
Chen YJ; Cheng PL; Huang WN; Chen HH; Chen HW; Chen JP; Lin CT; Tang KT; Hung WT; Hsieh TY; Chen YH; Chen YM; Hsiao TH
Front Immunol; 2022; 13():920865. PubMed ID: 35979368
[TBL] [Abstract][Full Text] [Related]
5. Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity.
Menon AR; Cherian S; Paul A; Kumar K; Ahmed S; Mehta P; Musthafa S; Gayathri B; Benny L; Shenoy P
Rheumatol Int; 2023 Mar; 43(3):449-457. PubMed ID: 36583801
[TBL] [Abstract][Full Text] [Related]
6. Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.
Benny L; Mehta P; Ahmed S; Paul A; Sukumaran A; Mohanan M; Vijayan A; Kaveri K; Padmaja R; Shenoy P
Rheumatol Int; 2023 Jun; 43(6):1033-1039. PubMed ID: 37029793
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Sirisreetreerux S; Porntharukchareon T; Dechates B; Rangsrisaeneepitak V; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
Sci Rep; 2023 Jul; 13(1):11798. PubMed ID: 37479776
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
[TBL] [Abstract][Full Text] [Related]
9. Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines.
Vijayan A; Sukumaran A; Jones S; Paul A; Ahmed S; Mehta P; Mohanan M; Kumar S; Easwaran S; Shenoy P
Cureus; 2024 Mar; 16(3):e55764. PubMed ID: 38586774
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
11. Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
Mohanasundaram K; Santhanam S; Natarajan R; Murugesan H; Nambi T; Chilikuri B; Nallasivan S
Int J Rheum Dis; 2022 Sep; 25(9):1046-1052. PubMed ID: 35773944
[TBL] [Abstract][Full Text] [Related]
12. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Dechates B; Monprach H; Sornsamdang G; Wittayasak K; Soonklang K; Mahanonda N
Hum Vaccin Immunother; 2022 Dec; 18(1):2035573. PubMed ID: 35240945
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G; Jungsomsri P; Sangwongwanich J; Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
Hum Vaccin Immunother; 2022 Nov; 18(5):2052525. PubMed ID: 35323079
[TBL] [Abstract][Full Text] [Related]
14. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
Cherian S; Paul A; Ahmed S; Alias B; Manoj M; Santhosh AK; Varghese DR; Krishnan N; Shenoy P
Rheumatol Int; 2021 Aug; 41(8):1441-1445. PubMed ID: 34142203
[TBL] [Abstract][Full Text] [Related]
15. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.
Skaria TG; Sreeprakash A; Umesh R; Joseph S; Mohan M; Ahmed S; Mehta P; Oommen SE; Benny J; Paulose A; Paul A; George J; Sukumaran A; Babu SS; Navas S; Vijayan A; Joseph S; Nalianda KK; Narayanan K; Shenoy P
Lancet Rheumatol; 2022 Nov; 4(11):e755-e764. PubMed ID: 36320825
[TBL] [Abstract][Full Text] [Related]
16. Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.
Nakafero G; Grainge MJ; Card T; Mallen CD; Nguyen Van-Tam JS; Williams HC; Abhishek A
Rheumatology (Oxford); 2023 Apr; 62(4):1445-1450. PubMed ID: 36048896
[TBL] [Abstract][Full Text] [Related]
17. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals.
Jeewandara C; Aberathna IS; Gomes L; Pushpakumara PD; Danasekara S; Guruge D; Ranasinghe T; Gunasekera B; Kamaladasa A; Kuruppu H; Somathilake G; Dissanayake O; Gamalath N; Ekanayake D; Jayamali J; Jayathilaka D; Mudunkotuwa A; Harvie M; Nimasha T; Wijayamuni R; Schimanski L; Rijal P; Tan TK; Dong T; Townsend A; Ogg GS; Malavige GN
Immun Inflamm Dis; 2022 Apr; 10(4):e592. PubMed ID: 35349749
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
Joudeh AI; Lutf AQ; Mahdi S; Tran G
Vaccine; 2023 Jun; 41(26):3801-3812. PubMed ID: 37244811
[TBL] [Abstract][Full Text] [Related]
20. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
